- Home
- CUE
as of 03-20-2026 3:41pm EST
$0.26
$0.00
-1.17%
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 27.8M | IPO Year: | 2017 |
| Target Price: | $3.00 | AVG Volume (30 days): | 762.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.28 | EPS Growth: | 61.11 |
| 52 Week Low/High: | $0.23 - $1.05 | Next Earning Date: | 03-16-2026 |
| Revenue: | $27,466,000 | Revenue Growth: | 195.75% |
| Revenue Growth (this year): | -13% | Revenue Growth (next year): | 25.00% |
| P/E Ratio: | -0.93 | Index: | N/A |
| Free Cash Flow: | -21864000.0 | FCF Growth: | N/A |
AI-Powered CUE Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 77.24%
77.24%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Cue Biopharma Inc. (CUE)
Sarraf Pasha
Buy
Director
CUE Dec 30, 2025
Avg Cost/Share
$0.31
Shares
323,857
Total Value
$99,747.26
Owned After
4,229
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Sarraf Pasha | CUE | Director | Dec 30, 2025 | Buy | $0.31 | 323,857 | $99,747.26 | 4,229 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Mar 16, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLMar 16, 2026 · 100% conf.
AI Prediction SELL
1D
-13.54%
$0.27
Act: -12.84%
5D
-19.74%
$0.25
20D
-24.99%
$0.23
Price: $0.31 Prob +5D: 0% AUC: 1.000
0001193125-26-108292
8-K
0001645460false00016454602026-03-162026-03-16
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 16, 2026
Cue Biopharma, Inc. (Exact name of registrant as specified in its charter)
Delaware
001-38327
47-3324577
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
40 Guest Street Boston, Massachusetts
02135 (Zip Code)
(Address of principal executive offices)
(617) 949-2680 (Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
CUE
Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02.
Results of Operations and Financial Condition.
On March 16, 2026, Cue Biopharma, Inc. issued a press release announcing financial results for the quarter and year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No.
Description
99.1
Press Release dated March 16, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Cue Biopharma, Inc.
Date: March 16, 2026
By:
/s/ Usman Azam
Name: Usman Azam
Title: President and Chief Executive Officer
2025 Q3 Q3 2025 Earnings
8-K SELL Nov 12, 2025 · 100% conf.
2025
Q3
Q3 2025 Earnings
8-K SELLNov 12, 2025 · 100% conf.
AI Prediction SELL
1D
-14.74%
$0.57
Act: -8.76%
5D
-21.41%
$0.52
Act: -13.09%
20D
-24.70%
$0.50
Act: -26.12%
Price: $0.67 Prob +5D: 0% AUC: 1.000
0001193125-25-277468
8-K
false000164546000016454602025-11-122025-11-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 12, 2025
Cue Biopharma, Inc. (Exact name of registrant as specified in its charter)
Delaware
001-38327
47-3324577
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
40 Guest Street Boston, Massachusetts
02135 (Zip Code)
(Address of principal executive offices)
(617) 949-2680 (Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
CUE
Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02.
Results of Operations and Financial Condition.
On November 12, 2025, Cue Biopharma, Inc. issued a press release announcing financial results for the quarter ended September 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No.
Description
99.1
Press Release dated November 12, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Cue Biopharma, Inc.
Date: November 12, 2025
By:
/s/ Usman Azam
Name: Usman Azam
Title: President and Chief Executive Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 12, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 12, 2025
0000950170-25-107268
8-K
false000164546000016454602025-08-122025-08-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 12, 2025
Cue Biopharma, Inc. (Exact name of registrant as specified in its charter)
Delaware
001-38327
47-3324577
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
40 Guest Street Boston, Massachusetts
02135 (Zip Code)
(Address of principal executive offices)
(617) 949-2680 (Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
CUE
Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02.
Results of Operations and Financial Condition.
On August 12, 2025, Cue Biopharma, Inc. issued a press release announcing financial results for the quarter ended June 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No.
Description
99.1
Press Release dated August 12, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Cue Biopharma, Inc.
Date: August 12, 2025
By:
/s/ Daniel R. Passeri
Name: Daniel R. Passeri
Title: Chief Executive Officer
Latest Cue Biopharma Inc. News
CUE Breaking Stock News: Dive into CUE Ticker-Specific Updates for Smart Investing
Compare CUE vs Leading Stocks
See how CUE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CUE Cue Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.